[1] | McInnes IB and Schett G (2011). The pathogenesis of rheumatoid arthritis. New England Journal of Medicine, 365(23): 2205-2219. |
[2] | Scott DL, Wolfe F and Huizinga TW (2010). Rheumatoid arhtirits. Lancet, 376(9746): 1094-1108. |
[3] | Cambridge G, Perry HC, Nogueira L, Serre G, Parsons HM, et al. (2014). The effect of B-cell depletion therapy on serological evidence of B-cell and plasmoblast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment. J Autoimmun, 50: 67-76. |
[4] | Leandro MJ and Cambridge G (2013). Expression of B cell activation factor (BAFF) and BAFF binding receptor in rheumatoid arthritis. J Rheumatol, 40(8): 1247-1250. |
[5] | Vincent FB, Saulep-Easton D, Figgett WA, Fairfax KA, and Mackay F (2013). The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine & growth factor reviews, 24(3): 203-215. |
[6] | Vincent FB, Morand EF, Schneider P and Mackay F (2014). The BAFF/APRIL system in SLE pathogenesis. Nature Reviews Rheumatology, 10(6): 365-373. |
[7] | Lahiri A, Pochard P, Le Pottier L, Tobón GJ, Bendaoud B, Youinou P and Pers JO (2012). The complexity of the BAFF TNF-family members: implications for autoimmunity. Journal of Autoimmunity, 39(3): 189-198. |
[8] | Townsend MJ, Monroe JG and Chan AC (2010). B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunological Reviews, 237(1): 264-283. |
[9] | Woo YJ, Yoon BY, Jhun JY, Oh HJ, Min SW, Cho ML and Min JK (2011). Regulation of B Cell activating factor (BAFF) receptor expression by NF-KB signaling in rheumatoid arthritis B cells. Exp Mol Med, 43(6): 350-357. |
[10] | Mariette X (2012). How does BAFF activate B cells in patients with autoimmune diseases?. Arthritis Research & Therapy, 14(1): 106. |
[11] | Aletaha D, Neogi T, Silman AG, Funovits J, Felson DT, et al. (2010). 2010 rheumatoid arthritis classification criteria. Arthritis and rheumatism, 62(9): 2569-2581. |
[12] | Morais SA, Vilas-Boas A and Isenberg DA (2015). B-cell survival factors in autoimmune rheumatic disorders. Ther Adv Musculoskelet Dis, 7(4): 122-151. |
[13] | Wei F, Chang, Y and Wei W (2015). The role of BAFF in the progression of rheumatoid arthritis. Cytokine, 76(2): 537-544. |
[14] | Pyrpasopoulou A, Balaska E, Triantafyllou A, Anyfanti P, Aslanidis S and Douma S (2012). B cell activation factor levels in rheumatoid arthritis patients in response to treatment with biologics. J Interferon Cytokine Res, 32(7): 338-340. |
[15] | Hu J, Yu Y, Han H, Civoli F, Zhuang Y, Thomas J and Gupta S (2014). Development of a novel BAFF responsive cell line suitable for detecting bioactive BAFF and neutralizing antibodies against BAFF-pathway inhibiting therapeutics. Cells, 3(1): 79-91. |
[16] | Šenolt L, Kryštůfková O, Hulejová H, Kuklová M, Filková M, Cerezo LA and Pavelka K (2011). The level of serum visfatin (PBEF) is associated with total number of B cells in patients with rheumatoid arthritis and decreases following B cell depletion therapy. Cytokine, 55(1): 116-121. |
[17] | Kreuzaler M, Rauch M, Salzer U, Birmelin J, Rizzi M, et al. (2012). Soluble BAFF levels, inversely correlate with peripheral B cell numbers and the expression of BAFF receptors. J Immunol, 188(1): 497-503. |
[18] | Gaugler B, Laheurte C, Bertolini E, Pugin A, Wendling D, Saas P and Toussirot E (2013). Peripheral Blood B cell Subsets and BAFF/APRIL Levels and their Receptors are disturbed in Rheumatoid Arthritis but not in Ankylosing Spondylitis. Journal of Clinical & Cellular Immunology, 4: 5. |
[19] | Moura RA, Cascão R, Perpétuo I, Canhão H, Vieira-Sousa E, Mourão AF and Souto-Carneiro MM (2011). Cytokine pattern in very early rheumatoid arthritis favours B-cell activation and survival. Rheumatology, 50(2): 278-282. |
[20] | Bosello S, Youinou P, Daridon C, Tolusso B, Bendaoud B, Pietrapertosa D and Ferraccioli G (2008). Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. The Journal of Rheumatology, 35(7): 1256-1264. |
[21] | Gottenberg JE, Miceli-Richard C, Ducot B, Goupille P, Combe B and Mariette X (2009). Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort. Arthritis Research & Therapy, 11(4): R114. |
[22] | Manzo A, Vitolo B, Humby F, Caporali R, Jarrossay D, Dell'Accio F and Pitzalis C (2008). Mature antigen-experienced T helper cells synthesize and secrete the B cell chemoattractant CXCL13 in the inflammatory environment of the rheumatoid joint. Arthritis & Rheumatism, 58(11): 3377-3387. |
[23] | Moura RA, Canhão H, Polido-Pereira J, Rodrigues AM, Navalho M, Mourão AF and Graca L (2013). BAFF and TACI gene expression are increased in patients with untreated very early rheumatoid arthritis. The journal of Rheumatology, 40(8): 1293-1302. |